Dr Shaun Pennington

Post-doctoral Research Associate

Shaun first graduated in 2010 with a BSc (Hons) in Biological Sciences from the University of Liverpool. Shaun returned to the University of Liverpool as a postgraduate student and graduated in 2011 with a MSc in Human Immunity. 

Shaun holds a PhD in Infection and Immunity from the University of Liverpool. The focus of his doctoral thesis was the assessment of the human immune response to oral vaccination with live-attenuated Salmonella Typhi.

Shaun’s immunological background has been applied for the study of host-pathogen interaction as well as for vaccine discovery and drug development

Shaun has been responsible for the management of the LSTM’s flow cytometry service and he currently manages the LSTM’s HG3 imaging facility.


Shaun’s research is currently focused on the development of in vitro models of typhoidal and non-typhoidal Salmonella infection for the study of bacterial pathogenesis and for use in the assessment of novel treatment strategies.

Selected publications

  • PENNINGTON, S. H., POJAR, S., MITSI, E., GRITZFELD, J. F., NIKOLAOU, E., SOLORZANO, C., OWUGHA, J. T., MASOOD, Q., GORDON, M. A., WRIGHT, A. D., COLLINS, A. M., MIYAJI, E. N., GORDON, S. B. & FERREIRA, D. M. 2016a. Polysaccharide-Specific Memory B Cells Predict Protection against Experimental Human Pneumococcal Carriage. Am J Respir Crit Care Med, 194, 1523-1531.

    PENNINGTON, S. H., THOMPSON, A. L., WRIGHT, A. K., FERREIRA, D. M., JAMBO, K. C., WRIGHT, A. D., FARAGHER, B., GILMOUR, J. W., GORDON, S. B. & GORDON, M. A. 2016b. Oral Typhoid Vaccination With Live-Attenuated Salmonella Typhi Strain Ty21a Generates Ty21a-Responsive and Heterologous Influenza Virus-Responsive CD4+ and CD8+ T Cells at the Human Intestinal Mucosa. J Infect Dis, 213, 1809-19.

    MITSI, E., ROCHE, A. M., REINE, J., ZANGARI, T., OWUGHA, J. T., PENNINGTON, S. H., GRITZFELD, J. F., WRIGHT, A. D., COLLINS, A. M., VAN SELM, S., DE JONGE, M. I., GORDON, S. B., WEISER, J. N. & FERREIRA, D. M. 2016. Agglutination by anti-capsular polysaccharide antibody is associated with protection against experimental human pneumococcal carriage. Mucosal Immunol.

    COLLINS, A. M., WRIGHT, A. D., MITSI, E., GRITZFELD, J. F., HANCOCK, C. A., PENNINGTON, S. H., WANG, D., MORTON, B., FERREIRA, D. M. & GORDON, S. B. 2015. First human challenge testing of a pneumococcal vaccine. Double-blind randomized controlled trial. Am J Respir Crit Care Med, 192, 853-8.

    FERREIRA, D. M., NEILL, D. R., BANGERT, M., GRITZFELD, J. F., GREEN, N., WRIGHT, A. K., PENNINGTON, S. H., BRICIO-MORENO, L., MORENO, A. T., MIYAJI, E. N., WRIGHT, A. D., COLLINS, A. M., GOLDBLATT, D., KADIOGLU, A. & GORDON, S. B. 2013. Controlled human infection and rechallenge with Streptococcus pneumoniae reveals the protective efficacy of carriage in healthy adults. Am J Respir Crit Care Med, 187, 855-64.